Natixis Advisors
MRVI icon

Natixis Advisors’s Maravai LifeSciences MRVI Stock Holding History

Natixis Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-413,417
Closed -$4.13M – 1548
2023
Q3 		$4.13M Buy
413,417
+25,743
+7% +$283K 0.01% 772
2023
Q2 		$4.82M Sell
387,674
-252,758
-39% -$3.41M 0.01% 715
2023
Q1 		$8.97M Buy
640,432
+169,287
+36% +$2.43M 0.03% 528
2022
Q4 		$6.74M Buy
471,145
+70,364
+18% +$1.11M 0.03% 596
2022
Q3 		$10.2M Sell
400,781
-24,598
-6% -$617K 0.04% 427
2022
Q2 		$12.1M Buy
425,379
+128,150
+43% +$4.06M 0.05% 392
2022
Q1 		$10.5M Buy
297,229
+158,299
+114% +$5.31M 0.04% 444
2021
Q4 		$5.82M Sell
138,930
-2,470
-2% -$100K 0.02% 617
2021
Q3 		$6.94M Buy
141,400
+3,716
+3% +$181K 0.03% 527
2021
Q2 		$5.75M Buy
137,684
+33,894
+33% +$1.31M 0.03% 588
2021
Q1 		$3.7M Buy
103,790
+41,976
+68% +$1.39M 0.02% 692
2020
Q4 		$1.73M Buy
+61,814
New +$1.72M 0.01% 875

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Natixis Advisors's MRVI Position: Q4 2023 in Review

Natixis Advisors sold out of Maravai LifeSciences (MRVI) in Q4 2023, closing a stake of 413,417 shares — an estimated $4.13M sold.

Natixis Advisors first reported a position in MRVI in Q4 2020 and held it in 12 quarters. The position peaked at $12.1M in Q2 2022. 223 funds tracked by Wall St. Rank hold MRVI as of Q4 2023.

  • Natixis Advisors reported no remaining Maravai LifeSciences position as of Q4 2023 after selling out during the quarter.
  • Natixis Advisors sold 413,417 Maravai LifeSciences shares in Q4 2023, an estimated $4.13M.
  • Natixis Advisors first reported a position in Maravai LifeSciences in Q4 2020 and held it in 12 quarters.
  • Natixis Advisors's Maravai LifeSciences position peaked at $12.1M in Q2 2022.
  • 223 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2023.

Based on Natixis Advisors's 13F filing for Q4 2023, filed 6 Feb 2024.